The Oncologist, Vol. 11, No. 2, 152-164, February 2006; doi:10.1634/theoncologist.11-2-152
© 2006 AlphaMed Press
Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents
David A. Reardona,
Patrick Y. Wenb
a Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA;
b Center for NeuroOncology, Dana Farber/Brigham and Womens Cancer Center, Boston, Massachusetts, USA
Key Words. Angiogenesis inhibitors • Glioblastoma multiforme • Targeted therapy • Tyrosine kinase inhibitors
Correspondence:
David A. Reardon, M.D., Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, DUMC 3624, Durham, North Carolina 27710, USA. Telephone: 919-684-3457; Fax: 919-684-6674; e-mail: reard003{at}mc.duke.edu and Patrick Y. Wen, M.D., Center for NeuroOncology, Dana Farber/Brigham and Womens Cancer Center, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-2166; Fax: 617-632-4773; e-mail: patrick_wen{at}dfci.harvard.edu
Despite advances in standard therapy, including surgical resection followed by radiation and chemotherapy, the prognosis for patients with glioblastoma multiforme (GBM) remains poor. Unfortunately, most patients die within 2 years of diagnosis of their disease. Molecular abnormalities vary among individual patients and also within each tumor. Indeed, one of the distinguishing features of GBM is its marked genetic heterogeneity. Nonetheless, recent developments in the field of tumor biology have elucidated signaling pathways and genes involved in the development of GBM, and several novel agents that target these signaling pathways are being developed. As new details on the genetic characteristics of this disease become available, innovative treatment regimens, including a variety of traditional treatment modalities such as surgery, radiation, and cytotoxic chemotherapy, will be combined with newer targeted therapies. This review introduces these new targeted therapies in the context of current treatment options for patients with GBM. It is hoped that this combined approach will overcome the current limitations in the treatment of patients with GBM and result in a better prognosis for these patients.
This article has been cited by other articles:

|
 |

|
 |
 
P. C. De Witt Hamer
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Neuro Oncology,
February 9, 2010;
(2010)
nop068v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Kim, R. Wustenberg, A. Rubsam, C. Schmitz-Salue, G. Warnecke, E.-M. Bucker, N. Pettkus, D. Speidel, V. Rohde, W. Schulz-Schaeffer, et al.
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells
Neuro Oncology,
January 27, 2010;
(2010):
nop046v1 - nop046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Dorsey, A. Mintz, X. Tian, M. L. Dowling, J. P. Plastaras, D. T. Dicker, G. D. Kao, and W. S. El-Deiry
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells
Mol. Cancer Ther.,
December 1, 2009;
8(12):
3285 - 3295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Calvio, M. Feuerstein, J. Hansen, and G. M. Luff
Cognitive limitations in occupationally active malignant brain tumour survivors
Occup. Med.,
September 1, 2009;
59(6):
406 - 412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Karpel-Massler, U. Schmidt, A. Unterberg, and M.-E. Halatsch
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Mol. Cancer Res.,
July 1, 2009;
7(7):
1000 - 1012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Vredenburgh, A. Desjardins, D. A. Reardon, and H. S. Friedman
Experience with irinotecan for the treatment of malignant glioma
Neuro Oncology,
February 1, 2009;
11(1):
80 - 91.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Reardon, K. L. Fink, T. Mikkelsen, T. F. Cloughesy, A. O'Neill, S. Plotkin, M. Glantz, P. Ravin, J. J. Raizer, K. M. Rich, et al.
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
J. Clin. Oncol.,
December 1, 2008;
26(34):
5610 - 5617.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology,
July 29, 2008;
71(5):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Diehn, C. Nardini, D. S. Wang, S. McGovern, M. Jayaraman, Y. Liang, K. Aldape, S. Cha, and M. D. Kuo
From the Cover: Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
PNAS,
April 1, 2008;
105(13):
5213 - 5218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Lefranc, V. Facchini, and R. Kiss
Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas
Oncologist,
December 1, 2007;
12(12):
1395 - 1403.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Brown and A. Law
Morphoproteomic Demonstration of Constitutive Nuclear Factor-kappaB Activation in Glioblastoma Multiforme with Genomic Correlates and Therapeutic Implications
Ann. Clin. Lab. Sci.,
January 1, 2006;
36(4):
421 - 426.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by AlphaMed Press.
|
|